Search clinical trials for: COPD, Chronic Obstructive Pulmonary Disease, Indacaterol, long acting β2-agonist

Total 95531 results

AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
Novartis
Schering-Plough

Completed

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

France, Germany, Belgium, Italy, Turkey, Hungary, Argentina, Peru, United Kingdom, South Africa, Latvia, Lithuania, Romania, Chile, Ireland, Norway, Poland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
AstraZeneca

Recruiting

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
Chronic Obstructive Pulmonary Disease Trial Network...

Recruiting

Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death From Any Cause

COPD Exacerbation

Denmark
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (BOREAS)

Chronic Obstructive Pulmonary Disease

Spain, Argentina, China, Mexico, Canada, Ukraine, Israel, Italy, Czechia, Korea, Republic of, Bulgaria, Chile, Denmark, Finland, Germany, Hungary, Japan, Poland, Romania, Russian Federation, Slovakia, Sweden, Turkey, United States
Elpen Pharmaceutical Co. Inc.

Completed

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination (RETRIEVE)

COPD | COPD Exacerbation

Greece
Riphah International University

Completed

Comparative Effects of ACBT and Slow Expiration in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Pakistan
Hywel Dda Health Board
Swansea University

Completed

sTep dOWn Inhalers in the reAl woRlD (TOWARD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Mylan Pharma UK Ltd.

Completed

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

COPD

China
Brigham and Women's Hospital
Johns Hopkins University; National Institute on Aging (NIA); Rutgers University

Active, not recruiting

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

Chronic Obstructive Pulmonary Disease

United States
Erasme University Hospital

Completed

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

Pulmonary Disease, Chronic Obstructive

Belgium
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

Pulmonary Disease, Chronic Obstructive

China
Boehringer Ingelheim

Completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Pulmonary Disease, Chronic Obstructive

China
Università degli Studi di Ferrara

Terminated

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Italy
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
University of Leicester
Genentech, Inc.; Biomedical Research Centre- Respiratory (Glenfield Hospital...

Completed

Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) (COPD-ST2OP)

COPD Exacerbation

United Kingdom
Boehringer Ingelheim
HealthCore-NERI

Completed

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Mylan Inc.
Theravance Biopharma

Completed

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

COPD

New Zealand
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

Pulmonary Disease, Chronic Obstructive

United States
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Centre Hospitalier Universitaire de Besancon

Completed

Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) (LAB-Card)

Chronic Obstructive Pulmonary Disease

France
Boehringer Ingelheim

Completed

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Pulmonary Disease, Chronic Obstructive

Denmark
Novartis Pharmaceuticals

Completed

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Chronic Obstructive Pulmonary Disease, COPD

Poland, United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
Bayside Health
Newcastle University; Austin Health

Completed

Effect of Exercise Training on Salivary Immunoglobulin A in Patients With Chronic Obstructive Pulmonary Disease

COPD

Australia
Daping Hospital and the Research Institute of Surgery...

Completed

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Chronic Obstructive Pulmonary Disease

China
GlaxoSmithKline

Completed

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Pulmonary Disease, Chronic Obstructive

China, Korea, Republic of
GlaxoSmithKline

Withdrawn

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study (LEGEND)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca
Parexel

Terminated

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.

Chronic Obstructive Pulmonary Disease

Germany
Boehringer Ingelheim

Completed

Effectiveness of Triple Therapy in COPD

Pulmonary Disease, Chronic Obstructive

United Kingdom
Novartis Pharmaceuticals

Completed

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

COPD

China
Novartis Pharmaceuticals

Completed

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (POWER)

Chronic Obstructive Pulmonary Disease

Canada
University of Dundee
Almirall Limited

Completed

Evaluation of Long-Acting Muscarinic Antagonists in COPD (MAN04)

Pulmonary Disease, Chronic Obstructive

United Kingdom
Pfizer

Completed

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. (A7881013)

Lung Diseases | Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive

United States, Croatia, Hungary, Bulgaria, Poland, Slovakia, Germany, South Africa, Argentina, Turkey, Spain, Czechia
AstraZeneca

Completed

DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (DETECT)

Chronic Obstructive Pulmonary Disease

Germany

3

Subscribe